Article
Gastroenterology & Hepatology
Linsong Mu, Yeli Wang, Hailong Su, Yang Lin, Wu Sui, Xiang Yu, Zhongchuan Lv
Summary: The study found that HIF1A-AS2 was elevated in gastric cancer tissues and promoted gastric cancer cell proliferation and metastasis by regulating the miR-429/PD-L1 axis. This provides a new insight into the search for novel biomarkers and therapeutic strategies.
DIGESTIVE DISEASES AND SCIENCES
(2021)
Article
Oncology
Christos Miliotis, Frank J. Slack
Summary: In gastric cancer, miR-105-5p has been identified as a key regulator of PD-L1 expression, impacting T cell activation, and could serve as a potential biomarker and target for combination immunotherapy targeting PD-1/PD-L1 interactions.
Article
Oncology
Birgid Schoemig-Markiefka, Jana Eschbach, Andreas H. Scheel, Aylin Pamuk, Josef Rueschoff, Thomas Zander, Reinhard Buettner, Wolfgang Schroeder, Christiane J. Bruns, Heike Loeser, Hakan Alakus, Alexander Quaas
Summary: This study optimized PD-L1 assessment in gastric cancer using endoscopically available tissue and found that CPS values from four surface biopsies can accurately reflect the PD-L1 status of the entire tumor. Preoperative biopsies showed lower sensitivity compared to tissue microarrays (TMAs).
Article
Immunology
Qi Zhang, Jing Pan, Donghai Xiong, Junjun Zheng, Kristi N. McPherson, Sangbeom Lee, Mofei Huang, Yitian Xu, Shu-hsia Chen, Yian Wang, Lea Hildebrandt Ruiz, Ming You
Summary: Delivery of aerosolized microRNAs targeting PD-L1 can effectively prevent the development and progression of lung cancer. In this study, aerosolized miR-138-5p and miR-200c miRNA mimics were found to inhibit B(a)P-induced lung adenomas and NTCU-induced lung squamous cell carcinomas with no detectable side effects. These miRNAs were also shown to inhibit PD-L1 expression and promote the immune response against cancer cells by increasing CD4+ and CD8+ T cells while reducing PD-1 expression and T-regulatory cells.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Yingzi Zhang, Yan Yang, Yiran Chen, Wu Lin, Xiangliu Chen, Jin Liu, Yingying Huang, Haiyong Wang, Lisong Teng
Summary: Gastric cancer is a major global cause of cancer incidence and mortality. The use of immune checkpoint inhibitors, particularly PD-L1/PD-1 inhibitors, has shown promising results in improving the prognosis of gastric cancer patients. Understanding the regulatory mechanisms of PD-L1 in gastric cancer could lead to significant progress in immunotherapy. Personalized treatment based on molecular characteristics could maximize clinical benefits and improve prognosis.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
TianWei Guo, Wei Wang, YueXia Ji, Min Zhang, GuoYing Xu, Sen Lin
Summary: The study revealed that PROX1-AS1 plays a role in gastric cancer progression through the miR-877-5p/PD-L1 axis, suggesting it may serve as a new therapeutic target for the diagnosis and treatment of GC patients.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Cell Biology
Anudari Letian, Eyoel Yemanaberhan Lemma, Paola Cavaliere, Noah Dephoure, Nasser K. Altorki, Timothy E. McGraw
Summary: PD-L1, a transmembrane ligand for immune checkpoint receptor PD1, has been successfully targeted to activate anti-tumor immune response in various solid tumors, including NSCLC. However, only a small percentage of patients respond to the treatment. This study reveals the growth factor control of PD-L1 recycling as a mechanism for regulating PD-L1 density on the plasma membrane, and identifies novel PD-L1 biology specific to mutant EGFR cells. The study also shows that anti-PD-L1 treatment affects mutant EGFR cells differently, leading to reduced cell migration, increased EGFR stability, and increased extracellular vesicle biogenesis.
CELL COMMUNICATION AND SIGNALING
(2023)
Article
Biochemistry & Molecular Biology
Zhenyan Miao, Jifei Li, Yu Wang, Mingqin Shi, Xiao Gu, Xuanqi Zhang, Fang Wei, Xinying Tang, Lufeng Zheng, Yingying Xing
Summary: This study reveals the oncogenic role of circRNA in gastric cancer and proposes a new pathogenic mechanism for the disease. It uncovers a novel role for hsa_circ_0136666 as an immune target and provides a rationale for enhancing the efficacy of anti-PD-L1 therapy for gastric cancer.
Article
Pharmacology & Pharmacy
Zhi-lu Ma, Yan-li Ding, Jing Jing, Lin-na Du, Xu-yang Zhang, Hong-min Liu, Peng-xing He
Summary: This study investigates the mechanism of all-trans retinoic acid (ATRA)-induced PD-L1 expression in gastric cancer cells and the impact of ATRA on cancer-associated immune suppression. The study reveals that ATRA enhances PD-L1 expression by increasing its protein stability and synthesis, which can be suppressed by the JAK pan-inhibitor ruxolitinib (RUX). Additionally, the upregulation of PD-L1 induced by ATRA renders gastric cancer cells resistant to T-cell killing, and blocking PD-L1 expression can inhibit tumor growth.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2022)
Article
Multidisciplinary Sciences
Kabsoo Shin, Joori Kim, Se Jun Park, Myung Ah Lee, Jae Myung Park, Myung-Gyu Choi, Donghoon Kang, Kyo Young Song, Han Hong Lee, Ho Seok Seo, Sung Hak Lee, Bohyun Kim, Okran Kim, Juyeon Park, Nahyeon Kang, In-Ho Kim
Summary: The study investigated the prognostic significance of soluble PD-L1 (sPD-L1) and exosomal PD-L1 (exoPD-L1) in patients with gastric cancer receiving chemotherapy. It was found that low levels of sPD-L1 and exoPD-L1 were associated with better overall survival and progression-free survival. Pretreatment sPD-L1 could be used as an independent prognostic factor for overall survival, while exoPD-L1 may reflect the immunosuppressive state of patients.
SCIENTIFIC REPORTS
(2023)
Article
Pharmacology & Pharmacy
Li Chen, Ruihu Zhao, Hao Sun, Rong Huang, Hongming Pan, Yanjiao Zuo, Lele Zhang, Yingwei Xue, Xingrui Li, Hongjiang Song
Summary: This study aimed to investigate the prognostic value of the gastric immune prognostic index (GIPI) in gastric cancer patients treated with PD-1/PD-L1 inhibitors. The results showed that patients with GIPI intermediate/poor had shorter progression-free survival (PFS) and overall survival (OS) compared to those with GIPI good, especially in subgroups of patients receiving immune checkpoint inhibitor (ICI) treatment and patients with PD-1/PD-L1 positive status. Therefore, GIPI may be useful for identifying gastric cancer patients who are unlikely to benefit from PD-1/PD-L1 inhibitor treatment.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Multidisciplinary Sciences
Changsheng Huang, Shengxiang Ren, Yaqi Chen, Anyi Liu, Qi Wu, Tao Jiang, Panjing Lv, Da Song, Fuqing Hu, Jingqing Lan, Li Sun, Xue Zheng, Xuelai Luo, Qian Chu, Keyi Jia, Yan Li, Jun Wang, Caicun Zou, Junbo Hu, Guihua Wang
Summary: This research discovered that PD-L1 K162 was methylated by SETD7 and demethylated by LSD2. Additionally, PD-L1 K162 methylation controlled the PD1/PD-L1 interaction and significantly enhanced the suppression of T cell activity in controlling cancer immune surveillance. The study demonstrated that PD-L1 hypermethylation was the key mechanism for anti-PD-L1 therapy resistance, identified PD-L1 K162 methylation as a negative predictive marker for anti-PD-1 treatment in patients with non-small cell lung cancer, and showed that the PD-L1 K162 methylation:PD-L1 ratio was a more accurate biomarker for predicting anti-PD-(L)1 therapy sensitivity.
Article
Oncology
Huimin Yang, Jinxiu Zhu, Rendong Xiao, Yuhang Liu, Fanglin Yu, Lin Cai, Minglian Qiu, Fei He
Summary: This meta-analysis evaluated the impact of EGFR mutation status on PD-1/PD-L1 immune checkpoint inhibitors in NSCLC patients, as well as the association between EGFR mutation status and PD-L1 expression. The results showed that immune checkpoint inhibitors significantly extended overall survival in NSCLC patients, particularly in the EGFR wild type subgroup, but not in the EGFR mutant subgroup.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Review
Biochemistry & Molecular Biology
Xianzhe Yu, Xiaoqian Zhai, Juan Wu, Qingbo Feng, Chenggong Hu, Lingling Zhu, Qinghua Zhou
Summary: Gastric cancer is a global health problem, and traditional therapies have limited efficacy. Immunotherapy using checkpoint inhibitors, particularly therapeutic antibodies targeting the PD-1/PD-L1 pathway, has made substantial breakthroughs in the treatment of gastric cancer.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
(2024)
Article
Pharmacology & Pharmacy
Yanzhen Chen, Jiayun Liu, Yuxuan Chen, Ruijuan Zhang, Jialei Tao, Xu Chen, Haidan Wang, Qingmin Sun, Jian Wu, Shenlin Liu
Summary: This study confirmed the inhibitory effect of Jianpi Yangzheng Xiaozheng decoction (JPYZXZ) on gastric cancer and elucidated its underlying mechanism involving PD-L1 expression. The study also revealed that JPYZXZ suppressed the delivery of exosomal PD-L1 from gastric cancer cells to bone marrow cells, alleviating the expansion of MDSCs and remodeling the immunosuppressive tumor microenvironment.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Chenlu Zhang, Zhi Li, Ling Xu, Xiaofang Che, Ti Wen, Yibo Fan, Ce Li, Shuo Wang, Yu Cheng, Xiaoxun Wang, Xiujuan Qu, Yunpeng Liu
Article
Oncology
Wei Li, Ling Xu, Xiaofang Che, Haizhou Li, Ye Zhang, Na Song, Ti Wen, Kezuo Hou, Yi Yang, Lu Zhou, Xing Xin, Lu Xu, Xue Zeng, Sha Shi, Yunpeng Liu, Xiujuan Qu, Yuee Teng
Article
Biochemistry & Molecular Biology
Kai Wang, Yanrong Li, Na Song, Xiaofang Che, Kezuo Hou, Ling Xu, Ming Bai, Qiwei Wang, Yuanhe Wang, Yang Zhou, Meihui Cao, Yunpeng Liu, Jingdong Zhang
JOURNAL OF CELLULAR BIOCHEMISTRY
(2019)
Review
Microbiology
Dan Zou, Ling Xu, Heming Li, Yanju Ma, Yuehua Gong, Tianshu Guo, Zhitao Jing, Xiuying Xu, Ye Zhang
CRITICAL REVIEWS IN MICROBIOLOGY
(2019)
Article
Oncology
Yibo Fan, Xiaofang Che, Jinglei Qu, Kezuo Hou, Ti Wen, Zhi Li, Ce Li, Shuo Wang, Ling Xu, Yunpeng Liu, Xiujuan Qu
ANNALS OF SURGICAL ONCOLOGY
(2019)
Article
Oncology
Bofang Liu, Ye Zhang, Yibo Fan, Shuo Wang, Zhi Li, Mingming Deng, Ce Li, Jin Wang, Rui Ma, Xiaoxun Wang, Yan Wang, Ling Xu, Kezuo Hou, Xiaofang Che, Yunpeng Liu, Xiujuan Qu
Article
Multidisciplinary Sciences
Ruoxi Yu, Zhi Li, Chuang Zhang, Huicong Song, Mingming Deng, Liping Sun, Ling Xu, Xiaofang Che, Xuejun Hu, Xiujuan Qu, Yunpeng Liu, Ye Zhang
Article
Plant Sciences
Mingming Deng, Bofang Liu, Huicong Song, Ruoxi Yu, Dan Zou, Yang Chen, Yanju Ma, Fei Lv, Ling Xu, Zhe Zhang, Qingjie Lv, Xianghong Yang, Xiaofang Che, Xiujuan Qu, Yunpeng Liu, Ye Zhang, Xuejun Hu
Article
Oncology
Shuairan Zhang, Yang Liu, Zihan Jiao, Zenan Li, Jin Wang, Ce Li, Xiujuan Qu, Ling Xu
Summary: This study identified seven independent prognostic factors of GSRCC and established corresponding nomogram models to help clinicians predict survival, showing good predictive value in comparison to the traditional AJCC staging system.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Shuo Wang, Xiujuan Qu, Zhi Li, Xiaofang Che, Lili Cao, Xianghong Yang, Xuejun Hu, Ling Xu, Kezuo Hou, Yibo Fan, Ti Wen, Yunpeng Liu
Summary: The study revealed that PD-L1 in ADC and PD-1+ TILs in SCC respectively indicate T-cell function, playing a crucial role in prognosis determination. PD-L1 was considered an independent predictor of overall survival for ADC patients, while PD-1+ TILs were deemed a poor prognostic predictor in SCC patients.
ANNALS OF TRANSLATIONAL MEDICINE
(2021)
Article
Cell Biology
Jinqi Lv, Simeng Zhang, Yang Liu, Ce Li, Tianshu Guo, Shuairan Zhang, Zenan Li, Zihan Jiao, Haina Sun, Ye Zhang, Ling Xu
Summary: This study demonstrates that NR2F1-AS1/miR-190a/PHLDB2 promotes the phosphorylation of AKT3 to induce EMT in GC cells, providing a comprehensive understanding of the underlying mechanism involved in the EMT process and the identification of new EMT markers in gastric cancer.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Education, Scientific Disciplines
Shuairan Zhang, Zhi Li, Hang Dong, Peihong Wu, Yang Liu, Tianshu Guo, Ce Li, Shuo Wang, Xiujuan Qu, Yunpeng Liu, Xiaofang Che, Ling Xu
Summary: The study identified 155 differentially expressed immune-related genes in patients with gastric cancer, with four genes closely associated with overall survival. These genes were found to be predictive of patient outcomes.
Article
Medicine, Research & Experimental
Jing Gong, Yongxi Song, Ling Xu, Xiaofang Che, Kezuo Hou, Tianshu Guo, Yu Cheng, Yunpeng Liu, Xiujuan Qu
MEDICAL SCIENCE MONITOR
(2020)
Article
Oncology
Xing Wan, Yongxi Song, Honghong Fang, Ling Xu, Xiaofang Che, Shuo Wang, Xiaomeng Zhang, Lingyun Zhang, Ce Li, Yibo Fan, Kezuo Hou, Zhi Li, Xueqing Wang, Yunpeng Liu, Xiujuan Qu
CLINICAL AND TRANSLATIONAL MEDICINE
(2020)